The purpose of this study is to investigate the effectiveness and safety of treatment with
clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to
treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have
been shown to have increases in certain inflammatory processes. Clazakizumab is an antibody
(immune system protein) that blocks certain inflammatory processes. The treatment plan is to
attempt to inhibit or block these inflammatory processes in order to try to limit the damage
COVID-19 causes to the lungs.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System